10.1056/nejmra2000317 139 WangL.LavierJ.HuaW.WangY.GongL.WeiH.et al (2021)
performed a cross-trial analysis using data from clinical trials of GLP-1RAs (ELIXA, LEADER, SUSTAIN-6, EXSCEL, HARMONY, REWIND, PIONEER-6 [59], and AMPLITUDE-O), SGLT2is (CANVAS and CREDENCE), and finerenone (FIDELIO-DKD and FIGARO-DKD) to estimate the effects of the triple combination therapy of GLP-1RA, SGLT2i, and finerenone using the actuarial method [60]
For all panels, data are presented as mean +/ SD, n = 3 biological replicates
Confirmation of identity and verification of purity for each component lot are essential, since an under-dosed, degraded or copper-depleted preparation will distort results
Standardization of methodologies across studies will also be essential to improve reproducibility and comparability
Exp Dermatol